Logo ofBasma Adeem Medical Co.
Investors start today, Jan. 13, subscription to Basma Adeem Medical Co.’s 4 million shares on the Nomu-Parallel Market. The price range was set between SAR 4 and SAR 4.4 a share. 
The shares on offer represent 25% of the company’s pre-IPO capital of SAR 16 million, divided into 16 million shares at a nominal value of SAR 1 each, and 20%of the post-IPO capital of SAR 20 million.
The subscription period for qualified investors will run for five days until Jan. 19.
Basma Adeem is the third offering on Nomu in 2025, after ITMAM Consulting Co. and Alshehili Co. on Jan. 5.
The parallel market witnessed 28 IPOs in 2024.
On Oct. 28, 2024, the Capital Market Authority (CMA) approved Basma Adeem’s request to register and float its shares on Nomu.
The subscription is limited to certain categories of investors, including capital market institutions authorized to act on their own accounts. This is in addition to clients of capital market institutions authorized to carry out management operations, provided they are appointed under terms that enable them to take decisions related to accepting participation in the share offering and investment in Nomu on behalf of clients without prior consent.
The categories include the Saudi government, any government, or international entity approved by the CMA, the Saudi market, any other financial market recognized by the CMA, or the Securities Depository CenterCo.(Edaa).
They also include companies owned by the government, directly or through a portfolio managed by a person authorized to practice management operations. This is in addition to investment funds, companies, and funds established in the GCC countries.
Additionally, the qualified investorsinclude anylegal or natural persons entitled to open investment accounts inside the Kingdom and with Edaa, provided they fulfill certain criteria,includingthe below:
They should have executed transactions in the capital markets worth a minimum of SAR 40 million and at least 10 deals in each quarter during the past 12 months.
Theyshould also have a net asset value of at least SAR 5 million and be working or have worked for at least three years in the financial sector.
They should hold a CMA-approved certificate in securities dealing and a professional certificate in the field of securities business, approved by an internationally recognized body.
The list of qualified investors also includes any other persons as defined by the CMA.
Company Profile
Basma Adeem Medical was founded in 2012 and is based in Riyadh. It was incepted as a limited liability company before becoming a closed joint-stock company.
The company’s actual activity is dentistry, offering treatment and cosmetic services. Its commercial registration lists additional activities, including specialty medical complexes, day surgery centers, medical clinics, and managing the operations of these facilities.
Company Profile
Company
Basma Adeem Medical Co.
Market
Nomu-Parallel Market
Core Activities
Dental treatment cosmetic dentistry
Pre-IPO Capital
SAR 16 mln
Current Number of Shares
16 mln
Post-IPO Capital
SAR 20 mln
New Number of Shares
20 mln
Par Value
SAR 1 per share
IPO Summary
Issue Percentage
20% of post-increase capital (25% of pre-IPO capital)
Offered Shares
4 mln
IPO Minimum Limit
100 shares
IPO Maximum Limit
999,900 shares
Offer Period
Five working days (Jan. 13-19)
Final Allocation
Jan. 22, 2025
Surplus Refund (If any)
Jan. 26, 2025
Company Shareholders
Shareholder
Pre-IPO
Post-IPO
Number of Shares
(‘000)
Ownership (%)
Number of Shares
(‘000)
Ownership (%)
Abdullah Al-Qadeeri
4030.03
25.19%
4030.03
20.15%
Mohammed Al-Buardi
3664.73
22.90%
3664.73
18.32%
Talal Al-Nassar
2748.88
17.18%
2748.88
13.74%
Mohammed Al-Sarhan
2015.67
12.60%
2015.67
10.08%
Treasury Shares
1600.00
10.00%
1600.00
8.00%
Sahmeen Investment
587.09
3.67%
587.09
2.94%
Farraj Al-Balawi
360.00
2.25%
360.00
1.80%
Nora Al-Sunaidi
288.00
1.80%
288.00
1.44%
Ibrahim Al-Oqeili
216.00
1.35%
216.00
1.08%
Abdulaziz Al-Bulaihis
144.00
0.90%
144.00
0.72%
Yazid Al-Buardi
86.40
0.54%
86.40
0.43%
Muteb Al-Qadeeri
86.40
0.54%
86.40
0.43%
Khalid Al-Nassar
86.40
0.54%
86.40
0.43%
Nora Al-Sahli
86.40
0.54%
86.40
0.43%
New Shares for QualifiedInvestors
—
—
4000
20.00%
Total
20000
100%
21000
100%
Board member Azzam Al-Mufdi holds a 1.83% indirect stake in the company’s pre-IPO share capital that will become 1.47% after the offering. This is given his 5% shareholding in Sahmeen Investment, which owns 3.67% and 2.94% of the company’s pre- and post-IPO shares, respectively.
Additional Information
Financial Advisor Lead Manager
Yaqeen Capital
Receiving Entities
Alinma Investment – Al Rajhi Capital – SNB Capital –Saudi Fransi Capital– Riyad Capital – ANB Capital – Alistithmar Capital – Albilad Capital – AlJazira Capital – GIB Capital – Alkhabeer Capital – SAB Invest – Sahm Capital – Derayah Financial
Logo ofBasma Adeem Medical Co.
Investors start today, Jan. 13, subscription to Basma Adeem Medical Co.’s 4 million shares on the Nomu-Parallel Market. The price range was set between SAR 4 and SAR 4.4 a share.
The shares on offer represent 25% of the company’s pre-IPO capital of SAR 16 million, divided into 16 million shares at a nominal value of SAR 1 each, and 20%of the post-IPO capital of SAR 20 million.
The subscription period for qualified investors will run for five days until Jan. 19.
Basma Adeem is the third offering on Nomu in 2025, after ITMAM Consulting Co. and Alshehili Co. on Jan. 5.
The parallel market witnessed 28 IPOs in 2024.
On Oct. 28, 2024, the Capital Market Authority (CMA) approved Basma Adeem’s request to register and float its shares on Nomu.
The subscription is limited to certain categories of investors, including capital market institutions authorized to act on their own accounts. This is in addition to clients of capital market institutions authorized to carry out management operations, provided they are appointed under terms that enable them to take decisions related to accepting participation in the share offering and investment in Nomu on behalf of clients without prior consent.
The categories include the Saudi government, any government, or international entity approved by the CMA, the Saudi market, any other financial market recognized by the CMA, or the Securities Depository CenterCo.(Edaa).
They also include companies owned by the government, directly or through a portfolio managed by a person authorized to practice management operations. This is in addition to investment funds, companies, and funds established in the GCC countries.
Additionally, the qualified investorsinclude anylegal or natural persons entitled to open investment accounts inside the Kingdom and with Edaa, provided they fulfill certain criteria,includingthe below:
They should have executed transactions in the capital markets worth a minimum of SAR 40 million and at least 10 deals in each quarter during the past 12 months.
Theyshould also have a net asset value of at least SAR 5 million and be working or have worked for at least three years in the financial sector.
They should hold a CMA-approved certificate in securities dealing and a professional certificate in the field of securities business, approved by an internationally recognized body.
The list of qualified investors also includes any other persons as defined by the CMA.
Company Profile
Basma Adeem Medical was founded in 2012 and is based in Riyadh. It was incepted as a limited liability company before becoming a closed joint-stock company.
The company’s actual activity is dentistry, offering treatment and cosmetic services. Its commercial registration lists additional activities, including specialty medical complexes, day surgery centers, medical clinics, and managing the operations of these facilities.
Company Profile
Company
Basma Adeem Medical Co.
Market
Nomu-Parallel Market
Core Activities
Dental treatment cosmetic dentistry
Pre-IPO Capital
SAR 16 mln
Current Number of Shares
16 mln
Post-IPO Capital
SAR 20 mln
New Number of Shares
20 mln
Par Value
SAR 1 per share
IPO Summary
Issue Percentage
20% of post-increase capital (25% of pre-IPO capital)
Offered Shares
4 mln
IPO Minimum Limit
100 shares
IPO Maximum Limit
999,900 shares
Offer Period
Five working days (Jan. 13-19)
Final Allocation
Jan. 22, 2025
Surplus Refund (If any)
Jan. 26, 2025
Company Shareholders
Shareholder
Pre-IPO
Post-IPO
Number of Shares
(‘000)
Ownership (%)
Number of Shares
(‘000)
Ownership (%)
Abdullah Al-Qadeeri
4030.03
25.19%
4030.03
20.15%
Mohammed Al-Buardi
3664.73
22.90%
3664.73
18.32%
Talal Al-Nassar
2748.88
17.18%
2748.88
13.74%
Mohammed Al-Sarhan
2015.67
12.60%
2015.67
10.08%
Treasury Shares
1600.00
10.00%
1600.00
8.00%
Sahmeen Investment
587.09
3.67%
587.09
2.94%
Farraj Al-Balawi
360.00
2.25%
360.00
1.80%
Nora Al-Sunaidi
288.00
1.80%
288.00
1.44%
Ibrahim Al-Oqeili
216.00
1.35%
216.00
1.08%
Abdulaziz Al-Bulaihis
144.00
0.90%
144.00
0.72%
Yazid Al-Buardi
86.40
0.54%
86.40
0.43%
Muteb Al-Qadeeri
86.40
0.54%
86.40
0.43%
Khalid Al-Nassar
86.40
0.54%
86.40
0.43%
Nora Al-Sahli
86.40
0.54%
86.40
0.43%
New Shares for QualifiedInvestors
—
—
4000
20.00%
Total
20000
100%
21000
100%
Board member Azzam Al-Mufdi holds a 1.83% indirect stake in the company’s pre-IPO share capital that will become 1.47% after the offering. This is given his 5% shareholding in Sahmeen Investment, which owns 3.67% and 2.94% of the company’s pre- and post-IPO shares, respectively.
Additional Information
Financial Advisor Lead Manager
Yaqeen Capital
Receiving Entities
Alinma Investment – Al Rajhi Capital – SNB Capital –Saudi Fransi Capital– Riyad Capital – ANB Capital – Alistithmar Capital – Albilad Capital – AlJazira Capital – GIB Capital – Alkhabeer Capital – SAB Invest – Sahm Capital – Derayah Financial
